This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
ResultsThe bibliometric analysis of COVID-19 and SuddenCardiacDeath highlights key research trends from 2020 to 2024, revealing a rapid surge in scientific output during the pandemic. Literature retrieved using the above keywords and published were included with a time limit from 1st January 2020 to 8th Aug 2024.ResultsThe
This study by Fujita Health University researchers revealed that kidney function, considered in terms of estimated glomerular filtration rate (eGFR), can be used as a predictor for SCD in patients with congestive heartfailure. During the follow-up period, 198 of these patients suffered from SCD.
Abstract Guidelines for management of heartfailure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision-making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence.
The implantable cardioverter-defibrillator (ICD) remains one of the most effective therapies for preventing suddencardiacdeath (SCD). Data supporting the role of primary prevention ICDs in patients with heartfailure were generated by rigorous randomized controlled trials (RCTs).1
Suddencardiacdeath (SCD) remains a pressing health issue, affecting hundreds of thousands each year globally. The heterogeneity among SCD victims, ranging from individuals with severe heartfailure to seemingly healthy individuals, poses a significant challenge for effective risk assessment.
A team of physicists has developed a groundbreaking method for detecting congestive heartfailure with greater ease and precision than previously thought possible.
The inherited heart condition often goes undiagnosed until it advances to heartfailure, which is why it’s important to identify those at risk and begin treatment early. heartfailure/heart transplant programs that contributed to the study. Eventually heartfailure may develop, which is late-phase disease.
This randomized clinical trial assesses whether cardioverter-defibrillator implantation is more effective than amiodarone therapy for the primary prevention of all-cause mortality and secondary prevention of suddencardiacdeath, hospitalization for heartfailure, and use of a pacemaker among patients with chronic Chagas cardiomyopathy.
The effects of SGLT2i on atrial fibrillation(AF), atrial flutter(AFL), composite AF/AFL, ventricular fibrillation(VF), ventricular tachycardia(VT), ventricular extrasystoles(VES), suddencardiacdeath(SCD) and composite VF/VT/SCD were evaluated. SGLT2i lowers the risk of SCD only in heartfailure patients.
Unlike a heart attack, cardiac arrest is an electrical malfunction that causes the heart to stop beating suddenly. This results in a failure to pump blood to the brain and other vital organs. Without immediate intervention, suddencardiacdeath can occur within minutes.
The main function of the implantable cardioverter-defibrillator (ICD) is to protect against suddencardiacdeath (SCD) due to ventricular tachyarrhythmia (VTA).
The aortic valve controls blood flow from the heart into the aorta, the main artery that feeds blood to most of the body. When the valve does not work correctly, patients may need a replacement to preserve function of the heart muscle and prevent issues such as heartfailure or suddencardiacdeath.
Suddencardiacdeath (SCD) risk stratification is based on clinically recognized risk factors (RF), such as reduced left ventricular (LV) ejection fraction (EF), heartfailure (HF), prior myocardial infarction (MI), and syncope. These RFs fail to capture the majority of SCDs.
The use of implantable cardioverter-defibrillators (ICD) for primary prevention (PP) of suddencardiacdeath among select patients with heartfailure (HF) is recommended by the HRS, AHA and ACC. However, whether ICDs may be underutilized within a safety-net system has not been studied.
Diabetes mellitus (DM) confers an increased risk of suddencardiacdeath (SCD) independent of its associated cardiovascular comorbidities. Diabetes mellitus induces adverse structural, electrophysiological, and autonomic cardiac remodeling which can increase one’s risk of ventricular arrhythmias and SCD.
Dilated cardiomyopathy (DCM) is a common heart muscle disorder of nonischemic etiology associated with heartfailure development and the risk of malignant ventricular arrhythmias and suddencardiacdeath.
Despite the abundance of evidence supporting the use of implantable cardioverter defibrillators (ICDs) for primary prevention of suddencardiacdeath (SCD), racial and gender inequities in ICD implantation persist.1,2
When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heartfailure and increased risk for suddencardiacdeath.
When the valve narrows, it does not open or close properly, making the heart work harder to pump blood throughout the body. Eventually, this causes the heart to weaken and function poorly, which may lead to heartfailure and increased risk for suddencardiacdeath.
“By adding AutoChamber AI to thoracic CT scans including coronary artery calcium (CAC) and coronary CT angiography (CCTA), doctors not only can evaluate coronary disease but also the risk of heartfailure, atrial fibrillation and stroke which are not reported today.
The following are key points to remember from a review article on cardiac implantable electronic devices (CIEDs), which include pacemakers for bradycardia, biventricular pacemakers for heartfailure, and implantable cardioverter–defibrillators (ICDs) for the treatment of suddencardiacdeath:
Hypertrophic cardiomyopathy (HCM) stands as one of the most common inheritable myocardial disease and is often marked by its association with suddencardiacdeath (SCD) in the young. 1 2 Traditionally, risk assessment in HCM has focused mainly on estimating the likelihood of SCD.
While reduced systolic function and heartfailure (HF) symptoms have been widely described, there is still a lack of reports about the arrhythmic manifestations of the disease. Peripartum Cardiomyopathy (PPCM) is a polymorphic myocardial disease occurring late during pregnancy or early after delivery.
The co-occurrence of keywords has generated 8 clusters, including DCM, lamin a/c, heartfailure, suddencardiacdeath, hypertrophic cardiomyopathy, cardiac hypertrophy, arrhythmogenic cardiomyopathy, and next-generation sequencing.
Publication date: 15 February 2024 Source: The American Journal of Cardiology, Volume 213 Author(s): Mohammed Al-Sadawi, Chad Gier, Michael Tao, Matthew Henriques, Paul Kim, Faisal Aslam, Ibrahim Almasry, Abhijeet Singh, Roger Fan, Eric Rashba
Non-caseating granulomatous infiltration of the myocardium is the hallmark of cardiac sarcoidosis (CS). CS manifests clinically as conduction disturbance, ventricular arrhythmia, suddencardiacdeath and/or heartfailure with reduced ejection fraction.
Implantable cardiac defibrillators (ICDs) are a fundamental therapy used in the prevention of suddencardiacdeath (SCD). With our aging population and with advances in medical therapy for heartfailure, navigating the decision-making process for ICDs in these patients(pts) becomes essential.
Clinical contexts leading to diagnosis were SCD in 3 (6%), ventricular arrhythmias in 15 (29%), chest pain in 8 (15%), heartfailure in 6 (12%) and familial screening in 20 (38%). Significant right ventricular involvement was an exclusion criterion.
Some of them may develop heartfailure, arrhythmias, thromboembolic events and even suddencardiacdeath rarely. When non-compaction is associated with left ventricular dysfunction it is called left ventricular non-compaction cardiomyopathy. Reference Thilde O. Kock, Marie F.
Post-MI cardiac remodeling leads to heartfailure and electrical aberrancies which result in lethal arrhythmias and suddencardiacdeath. Morbidity and mortality rates after Myocardial Infarction (MI) remain high despite advancements in therapy.
For the past four decades, implantable cardioverter defibrillator (ICD) therapy has become the standard of care for preventing suddencardiacdeath in high-risk individuals. The rate of ICD implantation has risen due to the increasing population age and the growing prevalence of cardiac arrhythmias.
Untreated OSA increases likelihood of poor outcomes for AFib patients including failed treatment, heartfailure, and suddencardiacdeath. Nearly 50% of patients with AFib have comorbid obstructive sleep apnea (OSA), and 75% of OSA patients report some form of arrhythmia.
Aims Timely referrals for transplantation and left ventricular assist device (LVAD) play a key role in favourable outcomes in patients with advanced heartfailure (HF). Cardiovascular mortality, driven by suddencardiacdeath, is the main reason for dying while waiting for heart transplantation (HTx).
WCD was assigned according to the Italian Association of Hospital Cardiologists position paper focussing on the appropriate use of WCD and European Society of Cardiology guidelines on ventricular arrhythmias and the prevention of suddencardiacdeath: 24 (58%) patients had a de novo diagnosis of heartfailure with reduced ejection fraction, 11 (27%) (..)
Non-ischemic cardiomyopathy (NICM) accounts for 30% of cases of heartfailure. Although pump failure is the most frequent cause of death in NICM, suddencardiacdeath (SCD) accounts for up to one third of all deaths.
Combined with standard care and prevention of suddencardiacdeath, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. It was based on an expert consensus reached at the HeartFailure Association online Workshop, held on 18 March 2021.
It presents in acute, indeterminate, and chronic phases, with chronic cardiomyopathy being the most severe form, leading to heartfailure, arrhythmias, and suddencardiacdeath. Introduction:Chagas disease is a significant cause of tropical disease-related mortality.
Compared to their peers without the condition, people with atrial fibrillation are twice as likely to be admitted to hospital, five times more likely to have a stroke, three times more likely to develop heartfailure, and twice as likely to die prematurely.4
CS has a range of clinical syndromes: impaired conduction, arrhythmias, heartfailure, and suddencardiacdeath. It is characterized by a dysregulated T-cell driven immune response which generates non-necrotic inflammatory granulomas with myocardial infiltration.
It is crucial for every medical physician to recognize patients who are at risk of suddencardiacdeath due to their underlying medical condition. It is crucial for every medical physician to recognize patients who are at risk of suddencardiacdeath due to their underlying medical condition.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content